MedPath

Envoy Medical Expands Patent Portfolio with Advanced Cochlear Implant Technologies

• Envoy Medical secures five new patents across US, Japanese, and Hong Kong jurisdictions for innovative cochlear implant technologies, strengthening their intellectual property portfolio in hearing health solutions.

• The US patents focus on breakthrough inner ear sensor technology and adjustable stereo cochlear implant systems, advancing the development of their fully implanted Acclaim Cochlear Implant.

• Japanese and Hong Kong patents cover integrated power supply systems, lead characterization, and accessory device pairing capabilities, expanding global protection for Envoy's cochlear implant innovations.

Envoy Medical Corporation (NASDAQ: COCH) has significantly strengthened its intellectual property position with the acquisition of five new patents across multiple international jurisdictions, advancing its innovative hearing health solutions portfolio.

US Patent Developments

The company secured two significant US patents in early 2025. The first, US Pat. No. 12,214,195, covers an implantable cochlear system featuring an innovative inner ear sensor technology. This system uniquely captures stimulus signals from cochlear tissue and fluid, processing them through both analog and digital stages to optimize frequency response.
A second US patent (No. 12,233,256) will be issued on February 25, focusing on adjustable stereo cochlear implant systems. This technology enables precise volume control between right and left cochlear implant subsystems, ensuring balanced hearing perception for users.

International Patent Expansion

In Japan, Envoy Medical secured three patents in December 2024. These patents address critical aspects of cochlear implant technology:
  • A unified power supply system for bilateral cochlear implants
  • Advanced lead characterization capabilities
  • Sophisticated signal processing for middle ear sensor inputs
Additionally, the Hong Kong Patent Office granted the company Patent No. HK40097814, protecting technology for seamless pairing of accessory devices with cochlear implant systems.

Clinical Innovation Pipeline

These patents support Envoy Medical's development of the Acclaim® Cochlear Implant, a groundbreaking fully implanted device that received FDA Breakthrough Device Designation in 2019. The Acclaim CI distinguishes itself by utilizing the ear's natural anatomy rather than external microphones for sound capture.
"These patents represent significant advancements in cochlear implant technology," states Envoy Medical's documentation. The company's innovative approach aims to address severe to profound sensorineural hearing loss cases where conventional hearing aids prove insufficient.

Market Position and Current Portfolio

The company's existing product line includes the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI), the only FDA-approved fully implanted hearing device for moderate to severe sensorineural hearing loss. This device offers unique advantages including 24/7 hearing capability without external components.
The expanded patent portfolio strengthens Envoy Medical's position in the hearing health market, particularly in fully implanted hearing solutions. These technological advances could potentially transform treatment options for patients with severe hearing impairments.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Envoy Medical Enrolls First Participants in Pivotal Acclaim Cochlear Implant Study

Envoy Medical has successfully enrolled the first two participants in its pivotal clinical study for the Acclaim cochlear implant.
The study aims to evaluate the safety and efficacy of the fully implanted Acclaim device for treating severe to profound sensorineural hearing loss.

MED-EL Cochlear Implant System Receives FDA Approval for Expanded Indications and Hearing Preservation

The FDA has approved expanded indications for the MED-EL Cochlear Implant System, allowing more adults with bilateral moderate-to-profound sensorineural hearing loss to qualify.
MED-EL is the first cochlear implant manufacturer to receive FDA approval for marketing claims related to the preservation of functional residual hearing after implantation.

MED-EL Cochlear Implant Receives FDA Approval for Expanded Indications and Hearing Preservation Claims

MED-EL's cochlear implant system secures FDA approval for expanded use in adults with moderate-to-profound sensorineural hearing loss, setting a new industry standard.
The approval includes the first-ever FDA endorsement for marketing claims related to the preservation of functional residual hearing after cochlear implantation.

Envoy Medical's Acclaim Cochlear Implant Pivotal Study Approved by FDA

Envoy Medical received FDA approval for its IDE application to begin a pivotal study of the Acclaim Fully Implanted Cochlear Implant, a novel hearing solution.
The Acclaim device uses the ear's natural anatomy to capture sound, differentiating it from traditional cochlear implants that rely on external microphones.

Envoy Medical Receives FDA Clearance to Study Acclaim Cochlear Implant

Envoy Medical received FDA approval for its IDE application to study the Acclaim cochlear implant, designed for adults with severe to profound sensorineural hearing loss.
The Acclaim CI utilizes an implanted sensor to capture sound, leveraging the ear's physical anatomy, and was previously granted breakthrough device designation in 2019.

Envoy Medical Receives FDA IDE Approval for Acclaim Cochlear Implant Study

Envoy Medical secured FDA approval for its IDE application to study the Acclaim cochlear implant in adults with severe to profound sensorineural hearing loss.
The Acclaim CI features an implanted sensor that leverages the ear's anatomy for sound capture, aiming to improve hearing outcomes for those inadequately served by hearing aids.

Envoy Medical's Acclaim Cochlear Implant Pivotal Study Receives FDA Green Light

Envoy Medical received FDA approval for its IDE application to begin a pivotal clinical study of the Acclaim® Fully Implanted Cochlear Implant, a novel hearing solution.
The Acclaim® device uses an implanted sensor to capture sound, leveraging the ear's natural anatomy, differentiating it from existing cochlear implants.

Envoy Medical's Acclaim Cochlear Implant Pivotal Study Receives FDA Approval

Envoy Medical received FDA approval for its IDE application to begin a pivotal study of the Acclaim® Fully Implanted Cochlear Implant, a novel hearing solution.
The Acclaim® device uses an implanted sensor to capture sound, leveraging the ear's natural anatomy, differentiating it from existing cochlear implants.

Envoy Medical Receives FDA Approval to Initiate Pivotal Study for Acclaim Cochlear Implant

Envoy Medical's Acclaim Fully Implanted Cochlear Implant receives FDA approval for its Investigational Device Exemption (IDE) application, allowing a pivotal clinical study to commence.
The Acclaim device uses an implanted sensor that leverages the ear's natural anatomy to capture sound, differentiating it from existing cochlear implants.

Envoy Medical's Acclaim Cochlear Implant Receives FDA Approval for Pivotal Clinical Study

Envoy Medical's Acclaim Cochlear Implant receives FDA approval for its Investigational Device Exemption (IDE) application, marking a significant step in its development.
The Acclaim device uses an implanted sensor to capture sound, differing from existing cochlear implants and potentially offering a more discrete option.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy